Accéder au contenu
Merck

[Primary hemostasis activity in patients with arterial hypertension and impaired glucose tolerance treated with trandolapril].

Klinicheskaia meditsina (2011-05-18)
V B Simonenko, I N Medvedev, O V Gamolina
RÉSUMÉ

The study was designed to evaluate effect of trandolapril, an ACE inhibitor, on platelet aggregation in patients with arterial hypertension and impaired glucose tolerance. The drug was given to 38 patients for 12 weeks. The key end points were dynamics of the blood lipid spectrum, lipid peroxidation in plasma and platelets, antioxidative protection of the blood's liquid medium and platelets, platelet aggregation. The data obtained were treated using Student's t-test. They show that trandolapril exerts positive effect on peroxidation syndrome and reduces platelet aggregation.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Trandolapril, ≥98% (HPLC), white, powder